Immunicum, a company engaged in the development of allogeneic, off-the-shelf cell-based therapies, is set to merge with DCprime, a company specialised in relapse vaccines, in a $72m deal. Van Herk Investments, DCprime majority shareholder and a European life science investor, will thereby become a significant shareholder of the combined entity. “Together, we can pursue the treatment of both solid tumor and blood-borne tumors by intratumoral priming as well as systemic boosting using the next-generation of allogeneic, off-the-shelf cell-based therapies. Our teams and our technologies are complementary and would significantly increase the potential of our pipeline and deliver more value-inflection points and potential partnering opportunities," Sven Rohmann, Immunicum MD, and CEO.